Business Context and Reporting Period
Company: CalciMedica, Inc. (Nasdaq: CALC)
Filing Type: Form 8-K (Current Report)
Report Date: May 12, 2026
Reporting Period: Fiscal quarter ended March 31, 2026
This filing serves as a notification that the company issued a press release on May 12, 2026, announcing its financial results for the quarter ended March 31, 2026. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The filing explicitly states that the detailed results are contained in the attached press release (Exhibit 99.1), which is not included in the input text.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended March 31, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued by the company but does not include the text of that release or any specific management commentary, guidance, or outlook within this document.
Legal Disclaimer: The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release) for actual revenue, net income, and cash position figures, as they are absent from the 8-K cover page.
- Verify the specific details of the fiscal quarter ended March 31, 2026, including any year-over-year growth or decline.
- Check for any forward-looking statements or updated guidance provided in the press release.
- Confirm the company's liquidity position and cash runway, which are critical for a biopharmaceutical entity like CalciMedica.